The Global Partnership for Zero Leprosy (GPZL) is a coalition committed to ending leprosy, also known as Hansen’s disease. Our members include individuals and organizations who share our triple-zero vision of no disease, no disability, and no discrimination or stigma.
Our Impact
- organizational members
- individual members
- country partnerships
- best practices
The Challenge
200,000 people
diagnosed each year
5 million people
living with leprosy-related disability and stigma
150 countries
with active transmission
130 laws
discriminate against people who have experienced leprosy
Our Strategy
Country Partnerships
We partner with national leprosy programmes and provide technical assistance to create country-led, customized strategies that address local needs and priorities to end leprosy.
Research
We convene experts to advance research priorities so we can reach zero leprosy faster.
Advocacy
We coordinate action to advance zero leprosy in international agendas and increase resources to end leprosy worldwide.
Zero Leprosy Toolkit
The Zero Leprosy Toolkit is a free set of field-tested best practices designed to support countries in their work toward ending leprosy and its associated disabilities and stigma.
Upcoming Events
13-15 September 2022
NNN Conference 2022
Read more >4 - 5 Oct 2022
COR-NTD 2022
Read more >Subscribe to Newsletter
Receive monthly updates on our progress toward zero leprosy and opportunities to get involved.
Recent News
11 July 2022
GPZL and partners sign the Abidjan Declaration
Partners signed the Abidjan Declaration, a commitment to mobilize the resources, both national and international, necessary for the implementation of the interventions of the Zero Leprosy Action Plan.
7 July 2022
Cambodia develops roadmap and action plan to end leprosy
In June 2022, the National Leprosy Programme of Cambodia, led by Dr Sambath Lay, hosted workshops in Phnom Penh to develop a Zero Leprosy Roadmap and Action Plan. Partners convened to outline strategies to bring the country closer to targets set forth by the WHO … Read More >